Federal contract award
75F40121C00127
EVALUATING THE IMPACT OF EXTENDED-INFUSION BETA-LACTAM ADMINISTRATION STRATEGIES ON IMPROVING CLINICAL OUTCOMES AND REDUCING THE SUBSEQUENT EMERGENCE OF ANTIMICROBIAL RESISTANCE-BAA-PMWP#173.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541720 — Research and Development in the Social Sciences and Humanities |
| PSC | AN41 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $307.0K |
| Current contract value | $307.0K |
| Potential contract value / ceiling | $307.0K |
| Start date | Sep 27, 2021 |
| Current end date | Sep 28, 2023 |
| Potential end date | Sep 28, 2023 |
| Latest award activity | Jul 12, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 4 of 4 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 12, 2026 | P00003 | $-171 | TO PROVIDE EVALUATING THE IMPACT OF EXTENDED-INFUSION ?-LACTAM ADMINISTRATION STRATEGIES ON IMPROVING CLINICAL OUTCOMES AND REDUCING THE SUBSEQUENT EMERGENCE OF ANTIMICROBIAL RESISTANCE -BAA-PMWP#173 |
| Jul 26, 2022 | P00002 | $0 | UPDATE INVOICING AND PAYMENT REQUIREMENTS. MAKE ACTION ELIGIBLE FOR SUBMISSION OF INVOICES THROUGH THE INVOICE PROCESSING PLATFORM (IPP). |
| Nov 30, 2021 | P00001 | $0 | EO14042 EVALUATING THE IMPACT OF EXTENDED-INFUSION BETA-LACTAM ADMINISTRATION STRATEGIES ON IMPROVING CLINICAL OUTCOMES AND REDUCING THE SUBSEQUENT EMERGENCE OF ANTIMICROBIAL RESISTANCE-BAA-PMWP#173. |
| Sep 27, 2021 | 0 | $307.2K | EVALUATING THE IMPACT OF EXTENDED-INFUSION BETA-LACTAM ADMINISTRATION STRATEGIES ON IMPROVING CLINICAL OUTCOMES AND REDUCING THE SUBSEQUENT EMERGENCE OF ANTIMICROBIAL RESISTANCE-BAA-PMWP#173. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 2404028639 | Source | May 26, 2021 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | May 26, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 2404028639 | Source | May 26, 2021 |
| Anthony S. Wimbush | Contact | anthony.wimbush@fda.hhs.gov 2404027628 | Source | May 26, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 2404028639 | Source | Jan 28, 2021 |
| Anthony S. Wimbush | Contact | anthony.wimbush@fda.hhs.gov 2404027628 | Source | Jan 28, 2021 |
| Benjamin Golway | Contact | Benjamin.Golway@fda.hhs.gov 3018374464 | Source | Nov 20, 2020 |
| Anthony S. Wimbush | Contact | anthony.wimbush@fda.hhs.gov 2404027628 | Source | Nov 20, 2020 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.